Literature DB >> 1281674

FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA.

J H Hanke1, L N Nichols, M E Coon.   

Abstract

The macrolides FK506 and rapamycin are potent immunosuppressive agents that inhibit the activation of T cells. Using Northern analyses and promoter-reporter constructs we analyzed the transcriptional and posttranscriptional effects of FK506 and rapamycin on IL-2, GM-CSF, and IL-2R alpha gene expression. FK506 completely inhibited activation of the IL-2 promoter, but only partially blocked GM-CSF promoter activity. In contrast, rapamycin only partially inhibited IL-2 and GM-CSF promoter activity. Interestingly, both FK506 and rapamycin also destabilized both IL-2 and GM-CSF mRNAs without influencing the stability of either the IL-2R alpha or GAPDH mRNA. These results show that both FK506 and rapamycin modulate IL-2 and GM-CSF gene expression at both the transcriptional and posttranscriptional level.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281674

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  4 in total

1.  The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication.

Authors:  Jocelyn Roy; Jean-Sébastien Paquette; Jean-François Fortin; Michel J Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease.

Authors:  Hiroyuki Tamaki; Hiroshi Nakase; Minoru Matsuura; Satoko Inoue; Sakae Mikami; Satoru Ueno; Norimitsu Uza; Hiroshi Kitamura; Katsuhiro Kasahara; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2008-10-29       Impact factor: 7.527

Review 3.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

4.  Identification and characterization of an Alu-containing, T-cell-specific enhancer located in the last intron of the human CD8 alpha gene.

Authors:  J E Hambor; J Mennone; M E Coon; J H Hanke; P Kavathas
Journal:  Mol Cell Biol       Date:  1993-11       Impact factor: 4.272

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.